Navigation Links
Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatism's Congress
Date:6/8/2011

NEW YORK, June 8, 2011 /PRNewswire/ -- One of the major annual rheumatology conferences, the European League Against Rheumatism's Congress (EULAR), was held May 25-28 in London.  Citeline, Inc., reviewed the trends and highlights from clinical trial results reported at EULAR, noting that approved biologics in rheumatoid arthritis dominated the program, comprising roughly 25% of clinical trial abstracts presented.  

Updates from long-term trials for approved biologics in RA—including adalimumab, etanercept, abatacept, rituximab and tocilizumab—provided further evidence of sustained clinical efficacy by standard measures, but also extended to reductions in joint damage (by radiographic and MRI methodologies), remission induction and effective treatment of early disease.  Of these approved biologics, tocilizumab trial results were the most numerous, and included several reports of treatment impact on serum lipid levels and other cardiovascular-related outcomes.  

Citeline's Senior Analyst in Autoimmune/Inflammation, Claire Herman, noted that the industry-wide interest in personalized medicine was evident at EULAR, with an array of abstracts presenting results from studies aimed at identifying biomarkers and pharmacogenomic markers as predictors of response to specific approved biologics. "This research is indicative of companies' focus on carving out individual niches within this highly competitive chronic disease arena," remarks Ms. Herman.  

Additionally, a number of these approved drugs' sponsors continue to focus on life-cycle management and expanded labeling, as evidenced by abstracts reporting results from trials of the subcutaneous formulation of abatacept (ALLOW and ACQUIRE), pivotal trials for Japanese approval of golimumab for RA, tocilizumab juvenile RA studies (TENDER), and rituximab combination therapies results. Trends in Trials for Approved Biologic Therapies in Rheumatoid ArthritisNumber of abstracts presented

Life-cycle management trials

Trials including structural outcomes in RA

Trials investigating biomarker/ pharmacogenomic predictors of responseCentocor's golimumab

7

2

3

-Abbott's adalimumab

9

-

2

2BMS's abatacept

10

5

2

3Roche/Biogen/Genentech's rituximab

14

2

2

5Roche's tocilizumab

28

3

2

7Novel therapeutics in RA were also showcased at EULAR. Citeline's Associate Director of Autoimmune/Inflammation, Dr. Laura Runkel, found several presentations from Pfizer to be most notable. Pfizer presented results from its ORAL Sync pivotal trial investigating tofacitinib in combination with traditional DMARDs, as well as data from its ORAL Solo trial, evaluating the oral JAK3 kinase inhibitor as monotherapy.  With the presentation of these results, Pfizer has now shared top-line data for all four of its tofacitinib pivotal trials.

"The company has announced plans to file for FDA and EMEA approval in a wide range of treatment combinations and patient populations by the end of 2011, representing the first filing for a biotechnology-derived, targeted oral treatment for RA," comments Dr. Runkel. "If the filings occur as planned, they will put tofacitinib far ahead of its closest competitor, Rigel/AstraZeneca's fostamatinib, whose syk kinase inhibitor is projected to complete pivotal trials in 2013."

About CitelineCiteline (www.citeline.com) provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 18,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:Julie McKenna
Citeline Marketing Manager
617.415.1981


'/>"/>

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 6, 2017  Medical professionals are expected ... while treating their patients. Medical simulations offer ... involving patients. Simulation provides a safe method ... out procedures, refine techniques and build confidence, ... new technology, such as augmented reality, will ...
(Date:9/5/2017)... , Sept. 5, 2017  Xyntek Inc. has announced another milestone in ... new Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West ... ... customer engagements regionally. ...
(Date:9/1/2017)... 1, 2017  Explorers Like Us ( https://explorerslikeus.com/ ) is ... experiences — and deliver these experiences as part of Life ... feel and heal better. ... While nothing beats a walk, jog or simply ... Life Environments™ is the next best thing when getting there ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... The ... “Humans With Vaginas.” The goal is to ignite conversation via social media and ... products. The brand has declared September “Humans with Vaginas” month, releasing a video ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... , ... “The Trials I Face to Receive God’s Grace”: a mesmerizing ... and goals to better one’s life through God. “The Trials I Face to Receive ... the wrong places, found a love for writing. Green feels that expressing his feelings ...
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... Houston, ... entire team took Friday, September 8, and Monday, September 11, off work and rolled ... Second Baptist Church before heading to local homes to start the process of rebuilding. ...
(Date:9/20/2017)... ... 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning ... author, Jeanine Liston, a busy mother of five who used her time waiting for children ... book for over twenty years. It was a way to give some meaning to ...
Breaking Medicine News(10 mins):